Giacomo Rossino

Dr. Giacomo Rossino

Department of Drug Sciences, University of Pavia, Pavia, Italy
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2023 in Molecules
Verified
Journal Article
Open access
PDF file
Giacomo RossinoGiacomo Rossino
Giacomo Rossino
Emanuela MarcheseEmanuela Marchese
Emanuela Marchese
GGGiovanni Galli
Giovanni Galli
FVFrancesca Verde
Francesca Verde
MFMatteo Finizio
Matteo Finizio
Simona CollinaSimona Collina
Simona Collina
Peptides are at the cutting edge of contemporary research for new potent, selective, and safe therapeutical agents. Their rise has reshaped the pharmaceutical landscape, providing solutions to challenges that traditional small molecules often cannot address. A wide variety of natural and modified peptides have been obtained and studied, and many others are advancing in clinical trials, covering multiple therapeutic areas. As the demand for peptide-based therapies grows, so does the need for sustainable and environmentally friendly synthesis methods. Traditional peptide synthesis, while effective, often involves environmentally draining processes, generating significant waste and consuming vast resources. The integration of green chemistry offers sustainable alternatives, prioritizing eco-friendly processes, waste reduction, and energy conservation. This review delves into the transformative potential of applying green chemistry principles to peptide synthesis by discussing relevant examples of the application of such approaches to the production of active pharmaceutical ingredients (APIs) with a peptide structure and how these efforts are critical for an effective green transition era in the pharmaceutical field.

5 August 2022 in Chirality
Verified
Journal Article
Open access
Giacomo RossinoGiacomo Rossino
Giacomo Rossino
Marina Simona RobescuMarina Simona Robescu
Marina Simona Robescu
ELEster Licastro
Ester Licastro
CTClaudia Tedesco
Claudia Tedesco
IMIlaria Martello
Ilaria Martello
Simona CollinaSimona Collina
Simona Collina
Over the last decades, biocatalysis has achieved growing interest thanks to its potential to enable high efficiency, high yield, and eco‐friendly processes aimed at the production of pharmacologically relevant compounds. Particularly, biocatalysis proved an effective and potent tool in the preparation of chiral molecules, and the recent innovations of biotechnologies and nanotechnologies open up a new era of further developments in this field. Different strategies are now available for the synthesis of chiral drugs and their intermediates. Enzymes are green tools that offer several advantages, associated both to catalysis and environmentally friendly reactants. Specifically, the use of enzymes isolated from biological sources or of whole‐cell represents a valuable approach to obtain pharmaceutical products. The sustainability, the higher efficiency, and cost‐effectiveness of biocatalytic reactions result in improved performance and properties that can be translated from academia to industry. In this review, we focus on biocatalytic approaches for synthesizing chiral drugs or their intermediates. Aiming to unveil the potentialities of biocatalysis systems, we discuss different examples of innovative biocatalytic approaches and their applications in the pharmaceutical industry.

Verified
Journal Article
Open access
PDF file
Giacomo RossinoGiacomo Rossino
Giacomo Rossino
MRMarta Rui
Marta Rui
LPLuca Pozzetti
Luca Pozzetti
DSDirk Schepmann
Dirk Schepmann
BWBernhard Wünsch
Bernhard Wünsch
Simona CollinaSimona Collina
Simona Collina
Sigma-1 receptor (S1R) is a promising molecular target for the development of novel effective therapies against neurodegenerative diseases. To speed up the discovery of new S1R modulators, herein we report the development of a reliable in silico protocol suitable to predict the affinity of small molecules against S1R. The docking method was validated by comparing the computational calculated Ki values of a test set of new aryl-aminoalkyl-ketone with experimental determined binding affinity. The druggability profile of the new compounds, with particular reference to the ability to cross the blood–brain barrier (BBB) was further predicted in silico. Moreover, the selectivity over Sigma-2 receptor (S2R) and N-methyl-d-aspartate (NMDA) receptor, another protein involved in neurodegeneration, was evaluated. 1-([1,1’-biphenyl]-4-yl)-4-(piperidin-1-yl)butan-1-one (12) performed as the best compound and was further investigated for acetylcholinesterase (AchE) inhibitor activity and determination of antioxidant activity mediated by aquaporins (AQPs). With a good affinity against both S1R and NMDA receptor, good selectivity over S2R and favorable BBB penetration potential together with its AChE inhibitory activity and its ability to exert antioxidant effects through modulation of AQPs, 12 represents a viable candidate for further development as a neuroprotective agent.

21 September 2017 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
DRDaniela Rossi
Daniela Rossi
MTMarilù Tarantino
Marilù Tarantino
Giacomo RossinoGiacomo Rossino
Giacomo Rossino
MRMarta Rui
Marta Rui
MJMarkus Juza
Markus Juza
Simona CollinaSimona Collina
Simona Collina
Introduction: Over the last 30 years, the scientific community has directed its efforts towards the identification of enantioselective approaches to obtain the desired active enantiomer. Accordingly, efficient production of single enantiomers from small to large scale, throughout Drug Discovery (DD) programs, has become of great interest and a fundamental challenge. Areas covered: This review focuses on two fundamental strategies for preparing enantiomers in high yields and with an excellent enantiomeric excess (ee). Separation of racemates, enantioselective synthesis procedures, and integrated approaches have been extensively reviewed, to offer a guide that enables the selection of the suitable methodology for producing pure enantiomers in scales from small to large. Expert opinion: Over the past two decades, drug regulatory agencies have set strict rules on the use of racemates and pure enantiomers, leading to the transformation of the drug market. Indeed, the number of drugs approved as a single enantiomer has exponentially increased, outclassing the racemic compounds. As a consequence, the academia and pharmaceutical companies are eager to develop efficient procedures for obtaining enantiopure compounds on the desired scale.

1 October 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MRMarta Rui
Marta Rui
Giacomo RossinoGiacomo Rossino
Giacomo Rossino
SCStefania Coniglio
Stefania Coniglio
SMStefania Monteleone
Stefania Monteleone
ASArianna Scuteri
Arianna Scuteri
Simona CollinaSimona Collina
Simona Collina

11 July 2019 in Frontiers in Chemistry
Verified
Journal Article
Open access
JVJosé Luis Velázquez-Libera
José Luis Velázquez-Libera
Giacomo RossinoGiacomo Rossino
Giacomo Rossino
CNCarlos Navarro-Retamal
Carlos Navarro-Retamal
SCSimona Collina
Simona Collina
JCJulio Caballero
Julio Caballero
The human Sigma1 receptor (S1R), which has been identified as a target with an important role in neuropsychological disorders, was first crystallized 3 years ago. Since S1R structure has no relation with another previous crystallized structures, the presence of the new crystal is an important hallmark for the design of agonists and antagonists against this important target. Some years ago, our group identified RC-33, a potent and selective S1R agonist, endowed with neuroprotective properties. In this work, drawing on new structural information, we studied the interactions of RC-33 and its analogs with the S1R binding site by using computational methods such as docking, interaction fingerprints, and receptor-guided alignment three dimensional quantitative structure–activity relationship (3D-QSAR). We found that RC-33 and its analogs adopted similar orientations within S1R binding site, with high similitude with orientations of the crystallized ligands; such information was used for identifying the residues involved in chemical interactions with ligands. Furthermore, the structure-activity relationship of the studied ligands was adequately described considering classical QSAR tests. All relevant aspects of the interactions between the studied compounds and S1R were covered here, through descriptions of orientations, binding interactions, and features that influence differential affinities. In this sense, the present results could be useful in the future design of novel S1R modulators.